ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-HER2/Anti-PD-1 Bispecific Antibody SSGJ-705

Also written as “SSGJ-705” and “SSGJ-705 combined with chemotherapy”.

Its studies are mostly in Neoplasms, led by 3SBio.

Drug pageAnti-HER2/Anti-PD-1 Bispecific Antibody SSGJ-705: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Jun 6, 20254 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
3SBio43 open or runningphase 2since Jun 6, 2025Nov 25, 2021Dec 2026phase 1 · NCT06390774

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 25, 2021First study: phase 1 study in Receptor, ErbB-2First studyNCT05145179 · 162 enrolled
  2. Apr 8, 2024Phase 1 study in RecurrenceNCT06390774 · 180 planned · China
  3. Jun 6, 2025Phase 2 study in RecurrenceNCT07022002 · 340 planned · China
  4. Jun 8, 2026Phase 2 study in Locally Advanced (Unresectable) or Metastatic Solid TumorsNCT07646626 · 150 planned · China

Ahead

  1. Dec 2026Primary completion: phase 1 study in RecurrenceNCT06390774
  2. Dec 31, 2026Primary completion: phase 2 study in RecurrenceNCT07022002
  3. Jun 30, 2027Primary completion: phase 2 study in Locally Advanced (Unresectable) or Metastatic Solid TumorsNCT07646626

TargetBeta

ERBB2 →PDCD1 →read by rule
“A bispecific antibody directed against the human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2) and the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07646626Locally Advanced (Unresectable) or Metastatic Solid Tumors · China2RecruitingJun 30, 2027150
NCT07022002Recurrence · China2RecruitingDec 31, 2026340
NCT06390774Recurrence · China1RecruitingDec 2026180
NCT05145179Receptor, ErbB-21UNKNOWNDec 1, 2023162

How it is read

Names in the registry

  • “SSGJ-705”, 4 entries
  • “SSGJ-705 combined with chemotherapy”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.